Anti-FGFR2/ BBDS/ BEK monoclonal antibody
Anti-FGFR2/ BBDS/ BEK antibody for FACS & in-vivo assay
Go to FGFR2/FGFR2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T58454-Ab-1/ GM-Tg-hg-T58454-Ab-2 | Anti-Human FGFR2 monoclonal antibody | Human |
GM-Tg-rg-T58454-Ab-1/ GM-Tg-rg-T58454-Ab-2 | Anti-Rat FGFR2 monoclonal antibody | Rat |
GM-Tg-mg-T58454-Ab-1/ GM-Tg-mg-T58454-Ab-2 | Anti-Mouse FGFR2 monoclonal antibody | Mouse |
GM-Tg-cynog-T58454-Ab-1/ GM-Tg-cynog-T58454-Ab-2 | Anti-Cynomolgus/ Rhesus macaque FGFR2 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T58454-Ab-1/ GM-Tg-felg-T58454-Ab-2 | Anti-Feline FGFR2 monoclonal antibody | Feline |
GM-Tg-cang-T58454-Ab-1/ GM-Tg-cang-T58454-Ab-2 | Anti-Canine FGFR2 monoclonal antibody | Canine |
GM-Tg-bovg-T58454-Ab-1/ GM-Tg-bovg-T58454-Ab-2 | Anti-Bovine FGFR2 monoclonal antibody | Bovine |
GM-Tg-equg-T58454-Ab-1/ GM-Tg-equg-T58454-Ab-2 | Anti-Equine FGFR2 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-T58454-Ab-1/ GM-Tg-hg-T58454-Ab-2; GM-Tg-rg-T58454-Ab-1/ GM-Tg-rg-T58454-Ab-2; GM-Tg-mg-T58454-Ab-1/ GM-Tg-mg-T58454-Ab-2; GM-Tg-cynog-T58454-Ab-1/ GM-Tg-cynog-T58454-Ab-2; GM-Tg-felg-T58454-Ab-1/ GM-Tg-felg-T58454-Ab-2; GM-Tg-cang-T58454-Ab-1/ GM-Tg-cang-T58454-Ab-2; GM-Tg-bovg-T58454-Ab-1/ GM-Tg-bovg-T58454-Ab-2; GM-Tg-equg-T58454-Ab-1/ GM-Tg-equg-T58454-Ab-2 |
Products Name | Anti-FGFR2 monoclonal antibody |
Format | mab |
Target Name | FGFR2 |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody, Cytokine antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-FGFR2 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Target information
Target ID | GM-T58454 |
Target Name | FGFR2 |
Gene ID | 2263,14183,25022,715949,415125,101095198,404193,100033956 |
Gene Symbol and Synonyms | BBDS,BEK,BFR-1,CD332,CEK3,CFD1,ECT1,FGFR,Fgfr-2,Fgfr-7,FGFR2,Fgfr2b,fgfr2IIIb,FGFR2IIIC,Fgfr7,JWS,K-SAM,KGFR,KGFRTr,svs,TK14,TK25 |
Uniprot Accession | P21802 |
Uniprot Entry Name | FGFR2_HUMAN |
Protein Sub-location | Transmembrane Protein |
Category | Therapeutics Target, INN Index, Cytokine Target |
Disease | Non-Small Cell Lung Cancer |
Gene Ensembl | ENSG00000066468 |
Target Classification | Kinase |
The target: FGFR2, gene name: FGFR2, also named as BBDS, BEK, BFR-1, CD332, CEK3, CFD1, ECT1, JWS, K-SAM, KGFR, TK14, TK25. The protein encoded by this gene is a member of the fibroblast growth factor receptor family, where amino acid sequence is highly conserved between members and throughout evolution. FGFR family members differ from one another in their ligand affinities and tissue distribution. A full-length representative protein consists of an extracellular region, composed of three immunoglobulin-like domains, a single hydrophobic membrane-spanning segment and a cytoplasmic tyrosine kinase domain. The extracellular portion of the protein interacts with fibroblast growth factors, setting in motion a cascade of downstream signals, ultimately influencing mitogenesis and differentiation. This particular family member is a high-affinity receptor for acidic, basic and/or keratinocyte growth factor, depending on the isoform. Mutations in this gene are associated with Crouzon syndrome, Pfeiffer syndrome, Craniosynostosis, Apert syndrome, Jackson-Weiss syndrome, Beare-Stevenson cutis gyrata syndrome, Saethre-Chotzen syndrome, and syndromic craniosynostosis. Multiple alternatively spliced transcript variants encoding different isoforms have been noted for this gene. [provided by RefSeq, Jan 2009].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.